For All the Quitter Talk About Funding
This last paragraph from page 6 of the current 10K.
Really crystalizes what the company is doing and
how important their work is. There will be no
shortage of funds for a CURE for an orphan status
disease in both Europe and The US.
(10K)
As we continue to manage our clinical trials and expand the indications for which our RPE cell therapy is being investigated, we have also begun to take the steps to define our final product formulation, as well as to lay the early ground work to support appropriate pricing, coverage and reimbursement programs. We believe that our RPE therapy provides pricing justification across all categories of consideration by Medicare, Medicaid, National Health Service (UK) and private payers. Our program related to RPE cell therapy for the treatment of SMD has been granted Orphan Drug status in both the U.S. and Europe, which could accordingly lead to provide regulatory market exclusivity and potential FDA grant opportunities.
(end 10K)
Pages 1 through 6 ought to be read by those who CAN read
and are capable of even rudimentary understanding.
It very clearly explains that OCATs therapy is a CELL
therapy, that is beyond conventional drugs.
